News

Patient Dies After Receiving Sarepta’s Gene Therapy
Sarepta Therapeutics said early Tuesday that a patient had died after receiving its gene therapy Elevidys, which treats the ...
In a first for St. Louis, patient completes new gene therapy to cure sickle cell disease
Martin Mwita, 20, is the first patient in St. Louis and among the first across the country to receive a new gene therapy for ...
Becker's Hospital Review17d
After patient’s death, study cites potential barrier to Elevidys
A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 in Gene Therapy suggests the body’s natural immune system might be ...
Yahoo Finance22d
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
In March, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy ... after the recent patient death due to ...
pharmaphorum2d
Pfizer pauses DMD gene therapy trial after boy’s death
The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted the company to pause dosing in another study.
Muscular Dystrophy News2d
Sarepta: Gene therapy Elevidys has given ‘hope’ to DMD community
It's been nearly two years since Elevidys, a gene therapy for Duchenne MD developed by Sarepta Therapeutics, was approved by ...
FiercePharma22d
UPDATE: After patient death, Sarepta and Roche pause 3 trials of gene therapy Elevidys in Europe
following the death of a 16-year-old patient in the U.S., Sarepta and Roche have temporarily halted three clinical trials in Europe of their Duchenne muscular dystrophy (DMD) gene therapy Elevidys.